Approval · Notice of Compliance 11054 · 2010
WARFARIN: Notice of Compliance 11054
Issued February 15, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11054
- Date
- February 15, 2010
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Anticoagulant
- Canadian reference product
- COUMADIN (Dupont Merck Pharma Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| WARFARIN | 02344025 | Cancelled Post Market |
| WARFARIN | 02344033 | Cancelled Post Market |
| WARFARIN | 02344041 | Cancelled Post Market |
| WARFARIN | 02344068 | Cancelled Post Market |
| WARFARIN | 02344076 | Cancelled Post Market |
| WARFARIN | 02344084 | Cancelled Post Market |
| WARFARIN | 02344092 | Cancelled Post Market |
| WARFARIN | 02344106 | Cancelled Post Market |
| WARFARIN | 02344114 | Cancelled Post Market |
Medicinal ingredients
- WARFARIN SODIUM 1 MG per TAB
- WARFARIN SODIUM 2 MG per TAB
- WARFARIN SODIUM 2.5 MG per TAB
- WARFARIN SODIUM 3 MG per TAB
- WARFARIN SODIUM 4 MG per TAB
- WARFARIN SODIUM 5 MG per TAB
- WARFARIN SODIUM 6 MG per TAB
- WARFARIN SODIUM 7.5 MG per TAB
- WARFARIN SODIUM 10 MG per TAB